Corporation
Novartis Pharmaceuticals Canada Inc.
- Meetings this Parliament
- 36
- With MPs
- 15
- Since Nov 2021
- 93
- Active registrations
- 1
Most recent reported meeting: Sep 23, 2026.
Lobbying by Novartis Pharmaceuticals Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingWho they meet
Since the current Parliament opened.
MPs
- Karim Bardeesy Liberal 2
- Kristina Tesser Derksen Liberal 2
- Marjorie Michel Liberal 2
- Evan Solomon Liberal 1
- Jennifer McKelvie Liberal 1
- Michael Coteau Liberal 1
- Jeremy Patzer Conservative 1
- Tom Kmiec Conservative 1
- Marc Miller Liberal 1
- Mélanie Joly Liberal 1
- Mike Lake Conservative 1
- Mark Carney Liberal 1
Institutions
- House of Commons12
- Health Canada (HC)11
- Innovation, Science and Economic Development Canada (ISED)8
- Finance Canada (FIN)3
- Prime Minister's Office (PMO)2
- Privy Council Office (PCO)1
- Natural Resources Canada (NRCan)1
- Intergovernmental Affairs Secretariat (IGA)1
Registrations in effect
In-house (corporation) In effect since May 19, 2026
Filed by Dimitri Gitas, Country President
Lobbyists
- Guillaume Demers · Director - Public Affairs
-
Shona Kinley · Vice-President Public Affairs
Former public office holder
Formerly Special Assistant, Minister's Office, Health Canada (1996–1996)
Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canadian Heritage (PCH), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Natural Resources Canada (NRCan), Pacific Economic Development Canada (PacifiCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (9)Hide details
- The CUSMA renegotiation and issues related to the pharmaceutical industry in Canada.
- Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.
- Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA"
- Patented Medicines Regulations modernization as outlined in Budget 2026, that will leverage existing technology, enabling faster and more cost effective procedural processes.
- Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
- R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
- Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
- Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
- Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
Registration 962869-15599-43. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Mark Vineis (35), Dimitri Gitas (21), Andrea Marazzi (17), Christian Macher (14), Pedro Ferreira (6).
-
Reported by Mark Vineis · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
-
Reported by Mark Vineis · In-house (corporation)
- Meron Cheway · Director of Operations, Innovation, Science and Economic Development Canada (ISED)
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
-
Reported by Mark Vineis · In-house (corporation)
- Evan Solomon · Minister of AI and Digital Innovation, Innovation, Science and Economic Development Canada (ISED)
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Jeremy Patzer · Member of Parliament
Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework. Read more
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Marc Miller · Member of Parliament
Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework. Read more
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Karim Bardeesy · Member of Parliament
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Mike Lake · Member of Parliament
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Yash Nanda · Senior Policy Advisor, Prime Minister's Office (PMO)
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)
-
Reported by Mark Vineis · In-house (corporation)
- Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)
-
Reported by Mark Vineis · In-house (corporation)
- Phillip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Free trade agreements as they relate to biomanufacturing industry in Canada
-
Reported by Mark Vineis · In-house (corporation)
- Bryce McRae · Manager of Stakeholder Relations, House of Commons
- Andrew Evans · Manager of Stakeholder Relations, House of Commons
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more
Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
-
Reported by Mark Vineis · In-house (corporation)
- Greg Orenscsak · Deputy Minister, Health Canada (HC)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB) Read more
-
Reported by Mark Vineis · In-house (corporation)
- Mary Ng · Minister of International Trade, Global Affairs Canada (GAC)
- Niloo Boroun · Director of Policy, Global Affairs Canada (GAC)
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
-
Reported by Mark Vineis · In-house (corporation)
- Aaron Wudrick · Director of Policy, House of Commons
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Valerie Bradford · Member of Parliament, House of Commons
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Peter Fragiskatos · Member of Parliament
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Matt Jeneroux · Member of Parliament
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Pam Damoff · Member of Parliament, House of Commons
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
- Benoit Leduc · Manager, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Tom Kmiec · Member of Parliament, Calgary Shephard
HealthIndustry
-
Reported by Mark Vineis · In-house (corporation)
- Julie Fielder · Special Assistant to MP Kmiec, House of Commons
HealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.